Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Mol Cancer Ther. 2013 Feb 20;12(5):759–767. doi: 10.1158/1535-7163.MCT-12-0903

Figure 6. ARF 26-44 peptide activates apoptotic response in the p53 null tumor cells.

Figure 6

A, TUNEL and DAPI staining of CreERT2 Foxm1 fl/fl and p53 −/− thymic lymphoma and sarcoma cells treated with PBS, ARF 37-44 peptide (Mut) or ARF 26-44 peptide (WT). B, Quantification of percentage of TUNEL positive cells per field.